In the early 1980s, seminal studies by Rosenberg and colleagues showed that exposure of patient-derived peripheral blood mononuclear cells (PBMCs) to IL-2 alone generated cells that were able to recognize and kill tumor cells in vitro (4, 60, 61). The gene discussed is IL2; the disease is neoplasm.